Buscar resultados de ensayos clínicos
Indolent B Cell Lymphoma - 25 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: Sofosbuvir+Ledipasvir ±Ribavirin and Sofosbuvir+Ribavirin for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4) and Sofosbuvir+Ribavirin(G2) for Pts With Hepatitis C Virus Associated Indolent B-cell Lymphomas Condición:
Fecha: 2016-02-25 Intervenciones:
|
Completed |
Nombre del estudio: High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas Condición:
Fecha: 2009-05-06 Intervenciones: Drug: rituximab Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosi |
Recruiting |
Nombre del estudio: Indolent Non Follicular Lymphomas Prognostic Project Condición: Indolent B-Cell Lymphomas Fecha: 2016-09-06 Intervenciones: Other: Any treatment, watch and wait policy included Patients registered in the study despite their plan |
Recruiting |
Nombre del estudio: Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Condición:
Intervenciones: Drug: Ibrutinib Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (l |
Active, not recruiting |
Nombre del estudio: Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma Condición:
|
Recruiting |
Nombre del estudio: Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma Condición: Lymphoma Fecha: 2015-07-08 Intervenciones: Radiation: Radiation Therapy Participants receive radiation to entire involved orbit for a total dose of |
Recruiting |
Nombre del estudio: Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Condición:
|
Completed |
Nombre del estudio: VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma Condición:
Fecha: 2004-06-11 Intervenciones: Drug: VELCADE and rituximab |
Withdrawn |
Nombre del estudio: Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas Condición:
|
Not yet recruiting |
Nombre del estudio: Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma Condición:
Fecha: 2016-09-08 Intervenciones:
|